Small Cell Lung Cancer CRISPR Knockout Models for Drug Discovery

Small cell lung carcinoma (SCLC) accounts for approximately 13-15% of all lung cancers globally, with an estimated 250,000 new cases per year (WHO, 2020). It is strongly associated with tobacco smoking, with over 95% of patients reporting a history of smoking. The 5-year survival rate remains dismal at about 6-7% for all stages combined, and only 2% for metastatic disease (NCI SEER, 2023). Despite initial high response rates to chemotherapy and radiotherapy, most patients relapse within months, highlighting an urgent need for novel therapeutic strategies.

SCLC is an ideal model for mechanistic studies due to its near-universal inactivation of TP53 and RB1, a relatively simple genome compared to non-small cell lung cancer, and well-defined molecular subtypes (SCLC-A, N, P, Y). Public datasets from TCGA, COSMIC, and DepMap provide extensive genomic, transcriptomic, and dependency data. Key open questions include the role of intratumoral heterogeneity, mechanisms of chemoresistance, and identification of actionable vulnerabilities beyond DNA damage repair.

SCLC pathogenesis is driven by the following key pathways:

• • TP53/RB1 Inactivation: Loss of function in nearly all tumors, leading to unchecked cell cycle progression and genomic instability.
• • MYC Family Amplification: MYC, MYCL, and MYCN are amplified in ~20% of cases, driving proliferation and metabolic reprogramming.
• • NOTCH Signaling Dysregulation: Inactivating mutations in NOTCH1-4 are common, promoting neuroendocrine differentiation.
• • PTEN/PI3K/AKT Pathway: Loss of PTEN or activating mutations in PIK3CA occur in a subset, activating survival signaling.

Data from TCGA (2015) and COSMIC v99.

Key deregulated signaling networks in SCLC include:

• • DNA Damage Repair: Homologous recombination repair is often impaired due to TP53 loss, creating sensitivity to PARP inhibitors.
• • PI3K/AKT/mTOR: Activated in ~30% of cases via PTEN loss or PIK3CA mutation.
• • MYC Transcriptional Program: Drives expression of genes involved in ribosome biogenesis, cell cycle, and metabolism.
• • NOTCH-HES1 Axis: Loss of NOTCH signaling leads to upregulation of neuroendocrine markers like ASCL1.
• • BCL2 Family: BCL2 is overexpressed in many SCLC lines, contributing to apoptosis resistance.

Organoid models derived from patient tumors preserve heterogeneity and can be used for drug testing and co-culture with immune cells.

Common animal models for SCLC research include:

• • Patient-Derived Xenografts (PDX): Engraftment of human SCLC tumors in immunodeficient mice; retain tumor heterogeneity.
• • Genetically Engineered Mouse Models (GEMM): Conditional knockout of Trp53 and Rb1 in lung epithelium (adenoviral Cre) recapitulates human SCLC.
• • Induced Models: Subcutaneous or orthotopic injection of human SCLC cell lines into mice for rapid tumor formation.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications. For SCLC, common models include TP53 knockout, RB1 knockout, and MYC overexpression in a background of TP53/RB1 loss. These models allow researchers to study the functional impact of specific mutations in a controlled genetic background. Commercially available, sequence-verified knockout and knock-in cell lines accelerate drug discovery and target validation by providing reproducible, ready-to-use tools.

CRISPR knockout and knock-in lines are used to validate the role of candidate oncogenes and tumor suppressors. For example, introducing a TP53 knockout in a TP53 wild-type SCLC line confirms its role in chemoresistance. Similarly, knocking in a MYC amplification into a low-MYC line can drive proliferation and neuroendocrine marker expression.

Isogenic pairs (e.g., TP53 wild-type vs. knockout) are used in high-throughput drug screens to identify genotype-specific sensitivities. Resistance models can be generated by chronic exposure to drugs, followed by CRISPR editing to confirm resistance mechanisms (e.g., SLFN11 loss causing PARP inhibitor resistance).

CRISPR synthetic lethality screens in SCLC cell lines have identified vulnerabilities such as CHEK1, WEE1, and AURKA. By comparing isogenic lines with and without a specific mutation, researchers can pinpoint biomarkers that predict response to targeted therapies.